Orsiro Mission

Orsiro® Mission DES

Thinnest Drug-Eluting Stent System Offering Enhanced Deliverability.

Find out how Orsiro® Mission can benefit your daily practice 
Orsiro® Mission is a new drug-eluting stent system that offers advanced deliverability and an ultrathin strut design considered the thinnest available in the United States. It features the same proprietary design and innovative bioabsorbable coating with controlled drug release as the Orsiro stent. Improvements to the new Orsiro Mission DES system include a re-engineered delivery system and a new deep embedding process to improve deliverability further, including ‘best in class’ trackability and crossability2.
   Next level of deliverability1
   Ultrathin struts2
  Outstanding patient outcomes3  
To learn more, visit the Orsiro Mission website


Better push, track and cross

The next level of deliverability

1st in Push4

Transmits up to 57% more force from hub to tip4

Orsiro Mission DES Push

1st in Track4

Up to 30% less force needed to follow the path

Orsiro Mission DES Track

1st in Cross4

Up to 75% less force needed to successfully cross demanding anatomies

Orsiro Mission DES Cross

Explore our extensive clinical program

Outstanding patient outcomes³

BIOFLOW-V Trial. TLF and components at 12, 24, and 36 Months
  • 40% lower TLF rate20ф (p = 0.003)
  • 46% lower TV-MI rate20ф (p = 0.004)
  • 52% lower Ischemia-driven TLR rate20ф (p = 0.008)
¤ p-values for 36-m frequentist analysis of BIOFLOW-V.20ф // ф vs. Xience, based on 36-m frequentist analysis of BIOFLOW-V.20


Discover why thinner struts make the difference

Ultrathin Struts

Orsiro Mission DES is an ultrathin strut2 that is considered the thinnest available in the U.S.6
• Less disrupted flow
• Improved re-endothelialization

* Nominal strut thickness for size ø 2.25 - 3.0 mm, mean diameter 62 μm.

Technical Data

Indication:  The Orsiro® Mission Sirolimus-Eluting Coronary Stent System is a drug-eluting balloon-expandable stent pre-mounted on a fast-exchange PTCA catheter delivery system. It is indicated for improving coronary luminal diameter in patients, including those with diabetes mellitus, with symptomatic heart disease, stable angina, unstable angina, non-ST-elevation myocardial infarction or documented silent ischemia due to atherosclerotic lesions in the native coronary arteries with a reference vessel diameter of 2.25 mm to 4.0 mm and a lesion length of ≤ 36 mm.

Technical Data Stent

Stent material Cobalt chromium, L-605

Passive coating proBIO™ amorphous silicon carbide

Active coating BIOlute™ bioabsorbable drug matrix consisting of

sirolimus and polymer poly-l-lactide (PLLA)

Nominal drug content 1.4 μg/mm²


Delivery system

Catheter type                                    Fast-exchange

Recommended guide catheter       5 F (min. I.D.Ж  0.056)

Guide wire diameter                         0.014 (0.36 mm)

Usable catheter length                    140 cm

Balloon material                               Semi crystalline polymer

Coating (distal shaft)                        Hydrophilic

Coating (proximal shaft)                  Hydrophobic

Marker bands                                   Two swaged platinum-iridium markers

Proximal shaft diameter                 2.0 F

Distal shaft diameter                       2.7 F: ø 2.25 – 3.0 mm; 2.9 F: ø 3.5 – 4.0 mm

Nominal pressure (NP)                    10 atm

Rated burst pressure (RBP)            16 atm 

ЖI.D. = Inner Diameter
Ordering Information

References1. In comparison to Xience Sierra, Resolute Onyx and Synergy for bench tests on pushability, trackability and crossability, BIOTRONIK data on file; 2. As characterized with respect to strut thickness in Bangalore et al. Meta-analysis; 3. Based on investigator’s interpretation of BIOFLOW-V primary endpoint result; 4. BIOTRONIK data on file; 5. Per investigators’ interpretation of preclinical studies with Orsiro as mentioned in Cassese et al. J Thorac Dis 2018;10(2):688-692; 6. When compared to FDA approved Drug Eluting Stents. BIOTRONIK data on file; 7. Foin N et al. International journal of cardiology. 2014 Dec 20;177(3):800-8; 8. Stefanini GG et al. Coronary stents: novel developments. Heart. 2014 Jul 1;100(13):1051-61; 9. Low AF. Stent platform for procedural success: Introducing the Continuous Sinusoidal & Core Wire Technologies. Presented at: AsiaPCR; 22-24 January, 2015; Singapore, Singapore; 10. Tolentino A. Evolving DES Strategy: Biodegradable Polymer vs. Bioabsorbable Scaffold. Presented at: Cardiovascular Nurse/Technologist Symposium; June 17, 2016; New York, USA; 11. Secco G et al. Time-related changes in neointimal tissue coverage of a novel Sirolimus eluting stent: Serial observations with optical coherence tomography. Cardiovascular Revascularization Medicine 2016; 17(1): 38-43; 12. Buiten R et al. Outcomes in patients treated with thin-strut, very thin-strut, or ultrathin-strut drug-eluting stents in small coronary vessels - A prespecified analysis of the randomized BIO-RESORT trial. JAMA Cardiol. 2019. doi:10.1001/jamacardio.2019.1776: Clinical Trials. gov: NCT01674803; 13. BIOTRONIK data on file, as of January 2020; 14. Taglieri N et al. Target lesion failure with current drug-eluting stents: Evidence from a comprehensive network meta-analysis. JACC 2020 13(24):2868-78; 15. Compared to Xience in BIOFLOW-V, based on three consecutive years; 16. Kandzari D et al. Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial. Lancet. 2017. 390(10105):1843-1852; 17. Kandzari D, et al. BIOFLOW-V: A Prospective Randomized Multicenter Study to Assess the Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in the Treatment Of Subjects With up to Three De Novo or Restenotic Coronary Artery Lesions Science. Presentation at ESC 2017; 18. Kandzari D et al. Ultrathin bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents. JACC. 2018. 72(25):3287-97; 19. Kandzari, D et al. Ultrathin bioresorbablepolymer sirolimus-eluting stents versus thin durable polymer everolimus-eluting stents for coronary revascularization: 3-year outcomes from the randomized BIOFLOW V trial. JACC: Cardiovascular Interventions. 2020, doi: 10.1016/j. jcin.2020.02.019; 20. Kandzari D et al. D et al. Ultrathin bioresorbable-polymer sirolimus-eluting stents versus thin durable polymer everolimus-eluting stents for coronary revascularization: 3-year outcomes from the randomized BIOFLOW V trial. JACC: Cardiovascular Interventions. 2020. Supplementary material.
Orsiro, Orsiro Mission, proBIO and BIOlute are trademarks or registered trademarks of the BIOTRONIK Group of Companies. Synergy, Promus and Taxus are trademarks or registered trademarks of the Boston Scientific Group of Companies. Resolute, Integrity, Resolute Onyx and Resolute Integrity are trademarks or registered trademarks of the Medtronic Group of Companies. Xience and Xience Sierra are trademarks or registered trademarks of the Abbott Group of Companies. Biofreedom and BioMatrix are trademarks or registered trademarks of the Biosensors International Group. Cre8 is a trademark or registered trademark of the Alvimedica Group of Companies. Nobori is a trademark or registered trademark of the Terumo Group of Companies. Cypher is a trademark or registered trademark of the Cardinal Health Group of Companies.